Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window

Background Adenomyosis was found to have negative impacts on embryo implantation. Leukemia inhibitory factor (LIF), proposed to be a molecular marker for endometrial receptivity, works through the LIF receptor (LIFR) on both the embryo and the endometrium. We aimed to evaluate the endometrial expression of LIF and LIFR and its subsequent signaling in patients with adenomyosis during the window of implantation (WOI).

Endometrium was obtained during the WOI from patients with adenomyosis (age <45 years) who underwent hysterectomy and from age-matched controls who had no endometriosis or adenomyosis. The LIF and LIFR expressions were measured by polymerase chain reaction for messenger RNA expression, immunohistochemistry for protein intensity and localization, and immunofluorescent staining for colocalization. The ratio of signal transducer and activator of transcription 3 (STAT3) to extracellular signal-regulated kinase (ERK) phosphorylation was measured by Western blot of both the endometrium and the isolated human endometrial stromal cells (ESCs).

Patients with adenomyosis showed significantly and parallelly reduced LIF and LIFR expressions in the eutopic endometrium during WOI as compared with the control women and subsequently with remarkably reduced activation of STAT3 and ERK signaling. The significantly increased STAT3 and ERK phosphorylation induced by the LIF treatment in the cultured ESCs supported the linkage between the LIF–LIFR reaction and the signaling cascade.

Significant reduction in LIFR expression and the reduced activation of subsequent signaling strongly suggest a working model of how the implantation markers, LIF, may affect the endometrium of patients with adenomyosis. These molecular changes supported the declined implantation rates reported in patients with adenomyosis. Similar content being viewed by others

Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus—revisited. Am J Obstet Gynecol. 1972;112(5):583–593. Thain S, Tan HH. Approaches to adenomyomectomy. Gynecol Minim Invasive Ther. 2015;4(3):49–54. Liu X, Yu S, Guo SW. A pilot study on the use of andrographolide to treat symptomatic adenomyosis. Gynecol Minim Invasive Ther. 2014;3(4):119–126. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update. 1998;4(4):312–322. Huang CY, Wu KY, Su H, et al. Accessibility and surgical outcomes of transumbilical single-port laparoscopy using straight instruments for hysterectomy in difficult conditions. Taiwan J Obstet Gynecol. 2014;53(4):471–475. Maheshwari A, Gurunath S, Fatima F, Bhattacharya S. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–392. Thalluri V, Tremellen KP. Ultrasound diagnosed adenomyosis has a negative impact on successful implantation following GnRH antagonist IVF treatment. Hum Reprod. 2012;27(12):3487–3492. Maubon A, Faury A, Kapella M, Pouquet M, Piver P. Uterine junctional zone at magnetic resonance imaging: a predictor of in vitro fertilization implantation failure. J Obstet Gynaecol Res. 2010;36(3):611–618. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod. 2014;29(5):964–977. Tomassetti C, Meuleman C, Timmerman D, D’Hooghe T. Adenomyosis and subfertility: evidence of association and causation. Semin Reprod Med. 2013;31(2):101–108. Edwards RG. Human uterine endocrinology and the implantation window. Ann N Y Acad Sci. 1988;541:445–454. Arici A, Engin O, Attar E, Olive DL. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J Clin Endocrinol Metab. 1995;80(6):1908–1915. Vogiagis D, Marsh MM, Fry RC, Salamonsen LA. Leukaemia inhibitory factor in human endometrium throughout the menstrual cycle. J Endocrinol. 1996;148(1):95–102. Pawar S, Hantak AM, Bagchi IC, Bagchi MK. Mini review: steroid-regulated paracrine mechanisms controlling implantation. Mol Endocrinol. 2014;28(9):1408–1422. Stewart CL, Kaspar P, Brunet LJ, et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992;359(6390):76–79. Aghajanova L. Leukemia inhibitory factor and human embryo implantation. Ann N Y Acad Sci. 2004;1034:176–183. Tsai HD, Chang CC, Hsieh YY, Lo HY. Leukemia inhibitory factor expression in different endometrial locations between fertile and infertile women throughout different menstrual phases. J Assist Reprod Genet. 2000;17(8):415–418. Mariee N, Li TC, Laird SM. Expression of leukaemia inhibitory factor and interleukin 15 in endometrium of women with recurrent implantation failure after IVF; correlation with the number of endometrial natural killer cells. Hum Reprod. 2012;27(7):1946–1954. Franasiak JM, Holoch KJ, Yuan L, Schammel DP, Young SL, Lessey BA. Prospective assessment of midsecretory endometrial leukemia inhibitor factor expression versus alphanubeta3 testing in women with unexplained infertility. Fertil Steril. 2014;101(6):1724–1731. Giudice LC. Potential biochemical markers of uterine receptivity. Hum Reprod. 1999;14(suppl 2):3–16. Sharkey AM, Smith SK. The endometrium as a cause of implantation failure. Best Pract Res Clin Obstet Gynaecol. 2003;17(2):289–307. Cheng JG, Chen JR, Hernandez L, Alvord WG, Stewart CL. Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation. Proc Natl Acad Sci U S A. 2001;98(15): 8680–8685. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(pt 1):1–20. Graf U, Casanova EA, Cinelli P. The role of the leukemia inhibitory factor (LIF)—pathway in derivation and maintenance of murine pluripotent stem cells. Genes (Basel). 2011;2(1):280–297. Han CM, Wu KY, Su H, et al. Feasibility of transumbilical single-port laparoscopic hysterectomy using conventional instruments. Gynecol Minim Invasive Ther. 2014;3(2):47–49. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122(2):262–263. Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46(10):5419–5425. Padykula HA. Regeneration in the primate uterus: the role of stem cells. Ann N Y Acad Sci. 1991;622:47–56. Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004;70(6):1738–1750. Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Masuzaki H. Involvement of hepatocyte growth factor-induced epithelial-mesenchymal transition in human adenomyosis. Biol Reprod. 2015;92(2):35. Khan KN, Fujishita A, Kitajima M, Masuzaki H, Nakashima M, Kitawaki J. Biological differences between functionalis and basalis endometria in women with and without adenomyosis. Eur J Obstet Gynecol Reprod Biol. 2016;203:49–55. Arici A, Head JR, MacDonald PC, Casey ML. Regulation of interleukin-8 gene expression in human endometrial cells in culture. Mol Cell Endocrinol. 1993;94(2):195–204. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. Human chorionic gonadotropin contributes to maternal immuno-tolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003;171(5):2305–2313. Xiao Y, Sun X, Yang X, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril. 2010;94(1):85–89. Laird SM, Tuckerman EM, Dalton CF, Dunphy BC, Li TC, Zhang X. The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. Hum Reprod. 1997;12(3):569–574. Huang BS, Tsai HW, Wang PH, Twu NF, Yen MS, Chen YJ. Epithelial-to-mesenchymal transition in the development of adenomyosis. Gynecol Minim Invasive Ther. 2015;4(3):55–60. Yen CF, Wang HS, Lee CL, Liao SK. Roles of integrin-linked kinase in cell signaling and its perspectives as a therapeutic target. Gynecol Minim Invasive Ther. 2014;3(3):67–72. Hever A, Roth RB, Hevezi PA, et al. Molecular characterization of human adenomyosis. Mol Hum Reprod. 2006;12(12):737–748. Kusakabe KT, Abe H, Kondo T, Kato K, Okada T, Otsuki Y. DNA microarray analysis in a mouse model for endometriosis and validation of candidate factors with human adenomyosis. J Reprod Immunol. 2010;85(2):149–160. Chen YJ, Li HY, Chang YL, et al. Suppression of migratory/ invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors. Fertil Steril. 2010;94(6):1972–1979, e1-e4. Carrarelli P, Yen CF, Arcuri F, et al. Myostatin, follistatin and activin type II receptors are highly expressed in adenomyosis. Fertil Steril. 2015;104(3):744–752.e1. Sheth SS, Ray SS. Severe adenomyosis and CA125. J Obstet Gynaecol. 2014;34(1):79–81. Kil K, Chung JE, Pak HJ, et al. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol. 2015;185:131–135. Kijima S, Takahashi K, Kitao M. Expression of CA 125 in adenomyosis. Gynecol Obstet Invest. 1987;23(2):122–123. Yang Y, Zhang J, Han ZY, et al. Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function. Sci Rep. 2015;5:10034. Benagiano G, Brosens I, Carrara S. Adenomyosis: new knowledge is generating new treatment strategies. Womens Health. 2009;5(3):297–311. Leyendecker G, Herbertz M, Kunz G, Mall G. Endometriosis results from the dislocation of basal endometrium. Hum Reprod. 2002;17(10):2725–2736. Parrott E, Butterworth M, Green A, White IN, Greaves P. Adenomyosis—a result of disordered stromal differentiation. Am J Pathol. 2001;159(2):623–630. Mehasseb MK, Bell SC, Habiba MA. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction (Cambridge, England). 2009;138(2):341–350. Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011;95(7):2228–2235. 2235.e1. Pawar S, Starosvetsky E, Orvis GD, Behringer RR, Bagchi IC, Bagchi MK. STAT3 regulates uterine epithelial remodeling and epithelialstromal crosstalk during implantation. Mol Endocrinol. 2013;27(12):1996–2012. Cullinan EB, Abbondanzo SJ, Anderson PS, Pollard JW, Lessey BA, Stewart CL. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. Proc Natl Acad Sci U S A. 1996;93(7): 3115–3120. Lalitkumar S, Boggavarapu NR, Menezes J, et al. Polyethylene glycated leukemia inhibitory factor antagonist inhibits human blastocyst implantation and triggers apoptosis by down-regulating embryonic AKT. Fertil Steril. 2013;100(4):1160–1169. Barnard W, Bower J, Brown MA, Murphy M, Austin L. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses LIF mRNA. J Neurol Sci. 1994;123(1-2):108–113. van Eijk MJ, Mandelbaum J, Salat-Baroux J, et al. Expression of leukaemia inhibitory factor receptor subunits LIFR beta and gp130 in human oocytes and preimplantation embryos. Mol Hum Reprod. 1996;2(5):355–360. Author information Authors and Affiliations Corresponding authors Rights and permissions About this article Cite this article Yen, CF., Liao, SK., Huang, S. et al. Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window. Reprod. Sci. 24, 1176–1186 (2017). https://doi.org/10.1177/1933719116681515 Published: Issue date: DOI: https://doi.org/10.1177/1933719116681515